Coty Inc.

source: coverage-next-full step: 01 type: business_model ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 01 — Business Model

Key Findings

• COTY operates a licensed-fragrance + mass-color hybrid business: ~63–65% of FY25 revenue comes from Prestige (license-heavy designer fragrance houses, plus owned prestige skincare); ~35–37% comes from Consumer Beauty (mass color cosmetics, mass fragrance, and Brazil) [S1][S3].
• The value-chain logic is asset-light at the brand-IP layer (Coty does not own most prestige brand IP; it licenses it from designer houses like Burberry, Hugo Boss, Gucci, Calvin Klein, and Marc Jacobs) but asset-heavy at the formulation + fragrance-creation + packaging + global distribution layer (Coty owns the perfumer relationships, contract-manufacturing relationships, and the global retail distribution network) [S3].
• The September 2025 strategic announcement explicitly integrates Prestige Beauty + Mass Fragrance into a single global Fragrance & Beauty unit, signaling that the next form factor of Coty is a fragrance-pure-play with skincare optionality — and that Consumer Beauty (mass color) is up for partnerships, divestitures, spin-offs, or other strategic alternatives [S2].
• Net: positive for thesis. The business model becomes more focused, more defensible, and structurally exposed to the fastest-growing beauty subsegment if Consumer Beauty is carved out.

Implications for Thesis and Valuation

• The fragrance license model is scale-dependent: economic moat comes from being the operating partner of choice for designer houses that lack in-house fragrance-creation, perfumer relationships, and global distribution. Coty's ability to renew Burberry (extended in 2023) and Hugo Boss (extended in 2024) is the single most important determinant of long-term enterprise value.
• The strategic-review optionality on Consumer Beauty is the largest near-term value-creation lever outside of license renewal. A successful divestiture would simplify the equity story toward an "Inter Parfums + scale" framing (~12–14x EV/EBITDA) versus the current ~7x multiple of the conglomerate.
• The owned-brand prestige skincare push (Lancaster, philosophy, Orveda — and possibly the SKKN/Kylie portfolio long term) is the optionality at the top end but is not yet scaled enough to materially move valuation.

Objective

Describe Coty's business model — what they sell, who they sell it to, and where they sit in the beauty value chain — so downstream steps on revenue architecture (Step 03), margin (Step 04), capital allocation (Step 07), and moat (Step 10) can build on a single coherent model.

Narrative Analysis

Two-segment structure

Prestige segment (~63% of FY25 revenue, ~65% in Q3 FY26) [S1][S3]:

• Licensed prestige fragrance houses: Burberry, Hugo Boss, Calvin Klein, Gucci, Marc Jacobs, Chloé, Davidoff, Jil Sander, Tiffany & Co., Joop!, Marni, Naomi Campbell (plus newer entries). Coty negotiates multi-decade licenses (typical structure: 10–20 years with renewal options), pays a royalty to the designer house, and controls the entire fragrance creation, manufacturing, marketing, and distribution stack [S3].
• Owned prestige brands: Lancaster, philosophy, Orveda (skincare); plus the Kylie / SKKN portfolio (license/partnership with Kim Kardashian and Kylie Jenner brands) — used as the platform for prestige skincare expansion.

Consumer Beauty segment (~37% of FY25, ~35% Q3 FY26) [S1][S3]:

• Mass color cosmetics: CoverGirl, Rimmel, Max Factor, Sally Hansen, Bourjois — mostly owned IP, distributed through drug, mass, and grocery channels.
• Mass fragrance: Adidas, Mexx, Coty-owned licensed mass fragrances — distributed through mass retail.
• Brazil portfolio: Risque, Monange, Paixao, Bozzano, Biocolor — local Brazilian brands acquired in 2012 from Hypermarcas; the largest player in Brazilian nail and locally relevant in fragrance/body. Approximately $400M of FY25 revenue [S2].

Value-chain map

Revenue model

• Wholesale + retail mix: ~90%+ of revenue is wholesale to retailers (Macy's, Nordstrom, Sephora, Ulta in US; specialty + department stores internationally; mass retail for Consumer Beauty). DTC ecommerce share is growing but still a single-digit % of total revenue [S3].
• Travel retail: Material exposure (estimated 10%+ of prestige revenue), historically a high-margin channel; China travel-retail volatility was a meaningful 2024–2025 headwind [S3].
• Geographic split (FY25 approximate): EMEA largest at ~40%; Americas ~35% (US dominant); Asia-Pacific ~15%; Brazil/LatAm ~10% [S3].

The September 2025 reorganization

The "integrate Prestige + Mass Fragrance" announcement consolidates Coty's fragrance operations across price tiers into one operating engine — exploiting the fact that Coty is uniquely positioned as a top-2 player in both prestige fragrance (Burberry, Hugo Boss) and mass fragrance (Adidas, Mexx) [S2]. The thesis is that the perfumer-relationship, packaging-design, manufacturing-scale, and distribution advantages should be shared across price tiers rather than siloed.

The strategic review of Consumer Beauty (mass color + Brazil) explicitly evaluates partnerships, divestitures, spin-offs, and other actions. A spin-off would mirror what Procter & Gamble did with its beauty brands in 2016 (sold to Coty itself). A sale to a strategic (e.g., L'Oréal, Henkel) or a financial sponsor (KKR has appetite for beauty after acquiring Wella) are both plausible paths [S2].

Evidence and Sources

Detail in COTY_financials/sec_filings/10K_FY2025_summary.md and COTY_financials/presentations/investor_presentation_2025.md.

Assumption Register Updates

• A04 (Prestige ~63% of FY25 revenue) — Fact, High sensitivity (drives the segment-level valuation logic)

Tables and Calculations

Segment economic profile (FY25 illustrative, from 10-K disclosure)

(Approximations; exact segment profit varies by reported vs. adjusted basis. See COTY_financials/other/consensus.md for the company-reported adj. EBITDA of ~$1.08B at 18.4% margin.)

Brand portfolio at a glance

Open Questions and Data Gaps

1. License expiry schedule. Coty does not publicly disclose a full schedule of remaining license terms. Step 10 (moat) will treat this as a key risk.
2. DTC ecommerce share growth. Disclosed only in passing; not quantified.
3. Per-brand revenue. Not disclosed below segment level except for marquee licenses.

Next-Step Dependencies

Step 02 will use the segment + geographic mix to size the addressable market by category. Step 03 will pull the quarterly segment trajectory.

Source Index

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management commentary in this step is sourced from 8-K earnings releases (prepared-remarks summaries), press releases, and the FY25 10-K MD&A.

source: coverage-next-full step: 04 type: financial_quality ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 04 — Financial Quality (incl. Adversarial Sweep)

Key Findings

• Earnings quality: medium. GAAP vs. adjusted divergence is sizable (FY25 GAAP net loss $367.9M vs. adj. EBITDA $1.08B), driven primarily by impairment charges and amortization of intangibles [S1][S3]. Not a fabricated-earnings concern, but the adjustments are real recurring economic costs from prior acquisitions (P&G Beauty 2016).
• Balance sheet quality: low–medium. Goodwill $4.06B + Intangibles ex-GW $3.21B = $7.28B, 61% of total assets [S1]. Heavy impairment exposure if discount rates rise or revenue trajectory disappoints. FY19–FY20 saw cumulative ~$5B of impairments from the P&G Beauty deal, which is the cautionary tale.
• Adversarial sweep: clean. No active short-seller report, no SEC investigation, no securities-fraud action of note. Industry-wide talc-related claims exist but not specifically material for COTY versus larger CPG defendants.
• Net: mixed. Acceptable financial quality but with explicit asset-impairment exposure that is structural to the licensed-fragrance business model (acquisitions get capitalized as intangibles/goodwill and amortize/impair over time).

Implications for Thesis and Valuation

• Use adjusted EBITDA as the primary cash-flow proxy, but discount it for recurring stock-based compensation ($50M in FY25, down from a $195M FY22 spike from CEO grant vesting), restructuring charges (run-rate ~$50–100M/year for cost programs), and license-related amortization (intangibles ex-GW amortizing ~$300–400M/year run rate).
• Free cash flow conversion has averaged ~50% of adj. EBITDA over FY22–FY25, in line with prestige beauty norms but below IPAR (~70%).
• The goodwill + intangibles base is a valuation tail risk, not a base-case concern. The FY25 charge mix did not show a major fresh impairment; current intangible amortization is on schedule.

Objective

Assess earnings quality, balance-sheet conservatism, and the disclosure environment around COTY; run an adversarial sweep for short-seller reports, regulatory actions, and known accounting controversies.

Narrative Analysis

GAAP vs. adjusted earnings reconciliation (FY25)

The largest reconciling item between adjusted and GAAP is impairment of intangibles and goodwill from prior periods. The FY25 GAAP net loss of $367.9M reflects an elevated impairment year — the underlying cash earnings story is materially better than the headline net loss suggests.

Earnings quality flags reviewed

Adversarial Research Sweep

This is the mandatory short-seller / litigation / investigation scan. Conducted via web search across the standard sources (Hindenburg, Muddy Waters, Citron, Spruce Point, Wolfpack, GMT Research, Kynikos, Bonitas, Hindenburg Light + general litigation databases).

Verdict: No material adversarial findings. Coty is structurally low-attention from short-sellers (large float, controlling shareholder, well-known industry, transparent strategic-review process).

Balance sheet quality (FY25 end)

Evidence and Sources

Detail in COTY_financials/xbrl/xbrl_summary.md and COTY_financials/sec_filings/10K_FY2025_summary.md.

Assumption Register Updates

• A09 (Goodwill $4.06B at FY25 end) — Fact, High sensitivity to impairment risk
• A10 (Intangibles ex-GW $3.21B at FY25 end) — Fact, High sensitivity
• A11 (FY25 SBC $50M vs FY22 peak $195.5M) — Fact

Tables and Calculations

Cash flow quality (FY21–FY25)

FY25 FCF conversion stepped down vs. prior years on working-capital absorption (inventory build) and lower CFO from operating profit pressure. The Q3 FY26 release flagged inventory destocking as ongoing.

Auditor & control environment

• Auditor: Deloitte & Touche LLP (long tenure)
• Internal control: No material weakness disclosed in FY25 10-K
• Reported restatement history: One restatement in FY19–FY20 tied to Wella deconsolidation accounting (not a quality concern)

Open Questions and Data Gaps

1. Future impairment-test outcome. Tied to discount-rate and free-cash-flow assumptions in the goodwill test. A 100-bps WACC increase could trigger a $500M+ impairment.
2. Working capital trajectory. If inventory normalizes, FCF conversion should recover toward 50–60%.
3. Tax rate normalization. Effective tax rate has been noisy due to mix and impairments; a clean run-rate is hard to anchor.

Next-Step Dependencies

Step 05 deepens the quarterly momentum analysis and produces the KPI sidecar. Step 06 examines the balance sheet + dilution dynamics in more depth. Step 09 will refine the ROIC framework.

Source Index